| Metric | Value (₹ Cr) | vs Q1 FY27 |
|---|---|---|
| Revenue | 956.50 | 4.8% |
| Total Income | 985.30 | 5.7% |
| Expenditure | 858.90 | 5.0% |
| PBT | 126.40 | 4.6% |
| Net Profit | 79.20 | 9.5% |
| OPM | 15.69% | 0.73pp |
| NPM | 8.04% | 0.28pp |
| EPS | 4.71 | 9.3% |
Scale Achieved, Margins at Risk: Where Fractal's AI Bet Really Sits
Fractal crossed $100M in quarterly revenue and grew profit 139% YoY, but a sharp 225 basis point gross margin compression forces the real question: can management recover margins in H2, or is the AI talent investment a multi-quarter drag?
₹79.2 Cr
+139% YoY
~₹102 Cr
~10.7% NPM
44%
−225 bps YoY
16.2%
+123 bps despite gross margin hit
Fractal hit a milestone in Q2: ₹956.5 crore in revenue (~$115 million USD), up 20% year-over-year and 4.8% sequentially. Profit surged 139% to ₹79.2 crore. But that top-line momentum masks the quarter's central tension—a steep drop in gross margins that has forced management to delay recovery guidance from near-term to H2 FY27. Investors are now placing the entire valuation on execution of that H2 margin rebound.
The profit breakdown: reported vs. adjusted
Reported net profit of ₹79.2 crore includes a ₹23 crore loss from Fractal's 31.5% stake in Qure.ai, the AI diagnostics company undergoing restructuring after a USAID funding shutdown. Strip out that associate loss, and underlying net profit is roughly ₹102 crore, or 10.7% of revenue—the organic profitability baseline. The reported 8.0% NPM conflates margin expansion from SG&A discipline (real) with a temporary investment drag (expected to normalize).
Gross margin: the hinge
Gross margin slid to 44%, down 225 basis points year-over-year. Management attributed the hit to heavy investment in forward-deployed engineers (FDE)—AI talent stationed inside client organizations to accelerate outcomes and deepen engagement. The drag is material: roughly 279 basis points of the 225 basis point total decline. Delivery expense as a share of revenue jumped to 56% from 51% a year ago.
We have invested ahead of the curve which is reflected in the gross margin for the quarter, while operating leverage has continued in SG&A. There is a short-term impact as we have invested in AI engineering talent.
The bet: those FDE hires are not yet billing at full utilization, but they will drive future revenue growth and competitive positioning. Management guided for gross margin recovery in Q3 and Q4 as these engineers deploy and begin generating revenue. Meanwhile, SG&A margin improved sharply to 23.6% of revenue (down from 27% prior quarter), showing cost discipline, and enabling EBITDA margin to expand 123 basis points to 16.2% despite the gross margin pressure.
Crossed $100M USD revenue threshold
Q2 revenue ₹956.5 Cr ≈ $115M USD, up 20% YoY and 4.8% QoQ
Supported
Adjusted EBITDA grew 30% YoY vs 20% revenue growth
EBITDA margin 16.2%, up 123bps YoY; absolute EBITDA growth ~30% implied by margin expansion and revenue growth
Supported
Gross margin down 225bps due to AI talent investment
Gross margin 44%, down 225bps YoY. FDE cited as ~279bps of decline. Temporary per management guidance.
Supported
Products portfolio growing 39% YoY to ₹150Cr run rate
Products ₹38Cr in Q2, implying ~₹150Cr annualized; 39% YoY growth confirmed; still only 4% of total
Supported
TMT expected healthy sequential growth in Q2
TMT grew 6% sequentially—positive but below company 5% average. Below prior call's tone.
Slightly overstated
What shifted on this call
Products momentum: ₹150Cr annualized run rate (+39% YoY). Cogentiq gaining enterprise traction (Microsoft Retail/CPG Partner of Year; AWS expansion).
Client concentration declining: Top 10 fell to 51.7% from 53.2% QoQ. 58 clients above ₹1M annual revenue. Healthy base broadening.
Net Revenue Retention improved: NRR 115% in Q2 vs 112% prior quarter. Land-and-expand working.
Gross margin recovery pushed to H2: Q2 came in 44% vs 46% prior-call implied. FDE drag higher than expected.
TMT recovery weaker: 6% sequential vs company 5% average. Hyperscaler capex shift cited; H2 recovery expected.
DSO increased to 76 days from 71: Larger deal mix, but working capital headwind. Normalization expected by year-end.
Bull and bear
$100M revenue scale validates enterprise AI consulting positioning in an era of rapid model proliferation and customer uncertainty.
Profit leverage +139% YoY despite gross margin compression proves SG&A discipline and operating leverage are real.
Client quality improving: NPS 76, NRR 115%, top 10 concentration declining. Deepening relationships, not chasing volume.
Healthcare +79% YoY and naturally high-margin. AI investment appetite in this sector is durable, not cyclical.
Products +39% YoY gaining enterprise traction. Path to higher-margin licensing revenue is tangible.
Strong balance sheet: ₹1,728 crore cash including ₹608 crore IPO proceeds. No debt, dry powder for FDE investment or M&A.
Gross margin 44% is structural. Recovery to 46%+ required in Q3/Q4. Miss on timing = miss on valuation thesis. Execution risk is material.
CPG (largest vertical, ~15% of revenue) growing 11% YoY amid consolidation and inflation. Sequential decline in Q2 concerning.
TMT only 6% sequential despite recovery positioning. Hyperscaler capex shift toward infrastructure could extend weakness into FY28.
Products only 4% of revenue. $100M target by FY27 end requires 50%+ sequential growth and 78% CAGR. Early-stage risk is high.
DSO increased to 76 days. Larger deal mix is positive long-term but payment term extension pressures working capital near-term.
Qure.ai restructuring—₹23Cr loss drag (23% of reported profit). Expected to normalize but timing uncertain.
How the street is positioned
Fractal's stock is trading at ₹809.45 in a bullish trend with increasing volume. It sits above its 20-day (₹744) and 50-day (₹764) moving averages, confirming upward momentum. Yet at −27.4% from its all-time high of ₹1,115, the stock retains material discount to peak, reflecting skepticism on near-term margin recovery and products execution.
From the 52-week low of ₹696.30, Fractal has recovered +16.25%, rewarding the $100M milestone and margin recovery narrative. RSI at 59.8 is neutral—neither overbought nor oversold—indicating room for upside if execution validates the H2 margin rebound story.
Ownership flows show FII buying strength. FII holdings ticked up +39 basis points quarter-over-quarter to 40.87%, a modest but consistent accumulation signal. DII holdings declined slightly (−99bps to 12.26%), suggesting some domestic profit-taking or rebalancing. Promoter stake remains steady at 16.97%. The FII buying on the dip supports conviction in the long-term AI thesis, but magnitude is incremental, not aggressive.
The debate
Ranked risks for a holder
Gross margin recovery timing uncertain
HighManagement guided Q3/Q4 recovery, but FDE deployment billing depends on client win velocity and project cadence. A Q3 miss breaks the margin expansion thesis entirely; implies 10–15% downside.
CPG vertical consolidation and macro drag
MediumLargest vertical (~15% of revenue), growing 11% YoY vs 20% company average. Sequential decline in Q2. If H2 recovery stalls, overall growth trajectory misses consensus.
TMT sector relying on AI adoption acceleration
MediumOnly 6% sequential growth despite being recovery story. Hyperscaler capex pivot away from services could extend weakness into FY28, affecting 10%+ of revenue.
Products $100M roadmap execution
MediumRequires 50%+ sequential growth and 78% CAGR from a 4% revenue base. Early-stage platform adoption is unpredictable. Miss would lower profitability profile and growth narrative.
DSO increase and working capital drag
Low-Medium76 days vs 71 days prior. Larger deal mix is positive but extended payment terms compress cash conversion. Miss on normalization by year-end = ongoing drag on free cash flow.
Qure.ai loss dragging consolidated metrics
Low₹23Cr loss = 23% of reported profit. Expected to ease, but timing uncertain. Doesn't affect core Fractal but weights reported profitability and NPM.
What to watch next quarter
1 · Q3 gross margin recovery
The hinge. Even recovery to 45% sequentially validates management narrative. Stall at 44% or compression = thesis break.
2 · FDE deployment and revenue contribution
Billable FDE headcount and revenue generation metrics. Are FDE-driven revenues hitting ₹50–100 Cr annually? If so, margin recovery becomes credible.
3 · Large deals pipeline closure
Management forming large deals team. First quarterly wins and run-rate ($5M+/quarter) would validate premium positioning and justify DSO increase.
4 · Products portfolio velocity
Cogentiq licensing wins and quarterly revenue run-rate. Currently ₹38Cr per quarter; need acceleration to $25M+ per quarter to track $100M target by FY27 end.
5 · CPG and TMT stabilization
Sequential growth inflection in these verticals. Recovery to company average (5%+) signals macro tailwind. Flat = sector-specific issues persist.
The one number to track from here
Gross margin. That's it. The quarter proves Fractal can scale revenue and leverage SG&A. The debate is execution on margin recovery. If Q3 gross margin recovers to 45% or higher, the stock re-rates up (implied upside 15–20% to ₹925–970). If it stays at 44%, downside risk to re-test 52-week lows at ₹696 is real (−14–15%). For now, the company delivered on scale. H2 will answer whether the AI talent investment pays off on the margin line.
Fractal is no longer a mid-market consulting shop. At ₹957 crore in quarterly revenue (~$115M USD), it has reached enterprise scale. The profit growth (+139% YoY) shows management can leverage fixed costs while investing in growth. But the 225 basis point gross margin compression is real, and the recovery guidance (Q3/Q4) is the hinge on which the entire valuation swings. The market has rewarded the milestone (+16% from lows) but hasn't regained full faith (−27% from ATH). For holders, the quarter is neither catastrophe nor triumph—it's a pause and a test. Q3 gross margin will tell you which direction the stock goes next.
Milestone revenue hit amid margin investment; products accelerating
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met qualitative FY27 guidance (TMT recovery, products growth, R&D investment); no numeric prior targets to miss; transparent on near-term headwinds.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Fractal has reached the $100M revenue milestone with strong profit growth (+139% YoY) and solid client metrics (NPS 76, NRR 115%), positioning it well for the enterprise AI wave. However, gross margin compression to 44% (down 225bps), sequential weakness in CPG/TMT, and DSO creep to 76 days create near-term uncertainty; management guides recovery Q3/Q4 but execution risk remains.
₹956.5 Cr
Revenue · +20% YoY₹79.2 Cr
Reported PAT · +139% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue crossed $100M threshold this quarter
METQ2 revenue INR 957Cr (~$115M USD), up 20% YoY and 5% QoQ
Adjusted EBITDA grew 30% YoY vs 20% revenue growth
METAdjusted EBITDA margin 16.2%, up 123bps YoY; absolute growth 30% implied by margin expansion and revenue growth
Gross margin down 225bps due to AI talent investment
METGross margin 44%, down 225bps YoY; FDE (Forward Deployed Engineers) investment cited as temporary drag, expects recovery Q3/Q4
Products portfolio growing 39% YoY to INR 150Cr run rate
METProducts revenue INR 38Cr in Q2, implying ~INR 150Cr annualized; 39% YoY growth confirmed; still only 4% of total
TMT expected healthy sequential growth in Q2
OVERSTATEDTMT grew 6% sequentially (vs 30% overall), rebounding from prior weakness but still below company average
Earnings quality
What changed since the last call
Products revenue momentum accelerating
UpgradeINR 150Cr run rate, up 39% YoY vs INR 108Cr prior year; Cogentiq gaining traction with frontier labs (Microsoft Retail/CPG partner of year, AWS expansion).
Client concentration declining
UpgradeTop 10 fell from 53.2% to 51.7% QoQ; 58 clients now above $1M annual revenue (healthy base broadening despite CPG headwinds).
Net Revenue Retention improved
UpgradeNRR 115% in Q2 vs 112% in prior quarter; net client additions 5 points contributing to growth without becoming more concentrated.
Gross margin guide pushed to H2 recovery
DowngradeQ2 came in at 44% vs 46% implied by management tone in prior call; FDE talent drag (279bps impact) higher than anticipated; Q3/Q4 recovery now critical.
TMT vertical growth slowed to 6% sequentially
DowngradeBelow company 5% average despite prior call emphasis on 'healthy sequential growth'; hyperscaler capex shift and macro uncertainty cited; recovery expected in H2.
The Q&A
Analysts pressed hard on gross margin timing, CPG consolidation, Cogentiq burn, and DSO. Management held firm on margin recovery narrative, detailed FDE deployment rationale, and reaffirmed 22% EBITDA target. Some skepticism on products $100M ambition but no major concessions; tone professional and data-grounded.
Growth trajectory by vertical — Gaurav Rateria, Morgan Stanley
AnsweredHealthcare is naturally high-growth and profitable; invests in own growth, benefits from AI. CPG consolidation and inflation muting near-term; differences reflect industry dynamics not solution quality. Both have deep Fractal solutions.
Cogentiq products pipeline and revenue — Gaurav Rateria, Morgan Stanley
PartialCogentiq is 100% licensed revenue, early stage, gaining traction with frontier labs and enterprise. Deeper applications under construction; expects meaningful improvement in overall product economics by end of year.
Gross margin investment rationale — Gaurav Rateria, Morgan Stanley
AnsweredInvestments in FDE (Forward Deployed Engineers) are mostly not yet billable; meant for future revenue growth and competitive positioning. Gross margin will recover Q3/Q4 as these engineers deploy and bill clients.
CPG sequential decline and recovery — Adit Patil, ICICI Securities
PartialSequential decline is seasonal (Q2 is typically weaker due to budgets); no major discontinuation. Expecting growth to resume and CPG to be solid; one of the largest verticals. Consolidation impact reflected in growth rate but not a fundamental shift.
G&A cost outlook and operating leverage — Adit Patil, ICICI Securities
AnsweredG&A will grow slower than revenue; aiming for leverage. Rate of growth in G&A will be much lower than revenue growth overall, supporting profitability improvement. This will continue across FY27 and next fiscal.
TMT segment recovery and pipeline — Pritesh Thakkar, PL Capital
PartialTMT will see sequential recovery in Q3/Q4; sector is AI-starved. Fractal's AI solutions helping these companies significantly. Expect overall TMT performance to improve in next few quarters; remains important long-term vertical.
Fractal Alpha profitability path — Pritesh Thakkar, PL Capital
AnsweredApproaching break-even early end of this year with sequential improvement. Growth continuing in products at higher margin; overall profitability trending in right direction for next two quarters. Will be approaching break-even by end of FY27.
FDE billing and utilization timeline — Pritesh Thakkar, PL Capital
PartialRevenue per employee marginally up in rupees but lower in dollars due to capacity build. Enormous appetite for enterprise AI; investing now to build scale for FY28. Expect significant scale-up in next year.
Growth vs profitability strategy — Suyash Kela, Singularity Asset Management
AnsweredGrowth-profitability balance is investor agreement: maximize revenue growth while aiming for 22% EBITDA. This is the implicit contract with public investors. If private, might invest more heavily in R&D and FDE, but respecting this framework now.
Products revenue roadmap and $100M target — Anil Nahata, Parami Financial
PartialTarget is $100M run rate by FY27 end (~12 quarters from now). Early stages; measuring success by product traction (sales velocity, client wins, feature adoption). Aiming for meaningful growth trajectory sequentially; CAGR will take care of itself if momentum holds.
Qure.ai business outlook and valuation — Anil Nahata, Parami Financial
AnsweredQure.ai is fantastic asset; very profitable, 31.5% ownership. Market treats it as drag due to consolidated loss from USAID PEPFAR shutdown. Building stronger U.S. business now; excellent valuation. Expect it to perform well and be great company.
Service offerings and revenue breakup — Mohit Bhalla, Indium Investment Advisors
PartialRoughly 40% of revenue from enabling client growth; 30% from operational efficiency (supply chain, forecasting, risk); 10-15% from R&D innovation; 5% from long-term sustainability. Themes vary by company size/industry; not a full revenue buckets breakdown.
Guidance
Target $100M products revenue run rate by FY27 end
MediumCurrently INR 150Cr (~$18M quarterly). Requires acceleration to $25M+ per quarter (50%+ growth). Cogentiq gaining traction; execution risk on 78% CAGR.
Sequential revenue growth expected in H2 FY27 and Q1 FY28
MediumNear-term headwinds in CPG/TMT; large deal pipeline forming. Seasonal patterns suggest Q3 recovery. FDE investments expected to drive future growth.
Gross margin expected recovery in Q3/Q4 from 44% current
MediumFDE talent investments (~279bps drag) to normalize. Wage-hike timing effects (shifted to June) to dissipate. Targets improvement sequential and to near-46% range.
Target 22% EBITDA margin while maximizing revenue growth
HighCurrent EBITDA margin 16.2%; guided to 22% as public company target. Achieved 30% EBITDA growth YoY; leverage to continue improving profitability path.
SG&A to grow slower than revenue; operating leverage building
HighCurrently 23.6% of revenue (down from 27% prior quarter). G&A discipline guiding incremental margin expansion; critical to 22% EBITDA target.
R&D investment at 6.3% of revenue, INR 40Cr capitalized per quarter
HighSupporting Cogentiq, Asper.ai, products roadmap. Mix of expensed (FDE, AI talent) and capitalized (IP development). Expected to reach 10% of revenue target as products scale.
Risks the call surfaced
Gross margin compression
MediumGross margin fell to 44%, down 225bps YoY. FDE hiring expensive in near-term; Cogentiq investments not yet fully billable. Recovery timing uncertain.
CPG vertical consolidation
MediumCPG largest vertical, but client consolidation and inflation reducing demand. 11% YoY growth below company average; sequential decline in Q2.
TMT segment weakness
MediumTMT (Technology, Media, Telecom) growing only 6% sequentially and slowed significantly YoY. Hyperscaler capex shifting away from services towards infrastructure.
Working capital deterioration
LowDSO increased to 76 days from 71 days prior quarter. Signals larger deal mix with longer payment terms, but working capital headwind in near-term.
Qure.ai associate loss drag
LowFractal's 31.5% stake in Qure.ai (AI medical diagnostics) contributed INR 23Cr loss to Q2 consolidated results. Temporary but material margin headwind.
Products revenue execution risk
MediumFractal targeting $100M annualized products revenue by FY27 end, requiring 50%+ sequential growth from current INR 150Cr run rate. Requires sustained Cogentiq/platform adoption and enterprise sales acceleration.
Management
Score 8/10. Clear technical depth on AI/products/platforms (Cogentiq, Asper.ai, FDE architecture). Transparent on challenges (gross margin, CPG weakness, DSO, Qure loss). Candid on strategic tradeoffs (growth vs profitability for public company). Limited over-assertion but forward-looking confidence appropriate. Hit $100M revenue milestone; grew profit 139% YoY despite margin investment. Met qualitative Q1 guidance (TMT recovery, products growth, R&D spending). No formal numeric guidance to miss. Track record of delivering on multi-quarter themes (NPS, NRR, client broadening).
1 · Q3/Q4 FY27
Gross margin recovery as FDE investments normalize and wage-hike timing effects dissipate.
2 · Q4 FY27
Qure.ai profitability inflection expected; associate drag to ease on consolidated NPM.
3 · FY28
AI cost reduction (48% QoQ, 93% annually) reaches threshold enabling full enterprise AI deployment at scale.
However, gross margin compression to 44% (down 225bps), sequential weakness in CPG/TMT, and DSO creep to 76 days create near-term uncertainty; management guides recovery Q3/Q4 but execution risk remains.